Skip to main content
Premium Trial:

Request an Annual Quote

Multiplicom CLL MASTR Plus

Multiplicom has announced the commercial release of a new gene sequencing panel, the CLL MASTR Plus kit, to improve the diagnosis of patients with chronic lymphocytic leukemia. CLL MASTR Plus detects single nucleotide variants and copy number alterations in nine genes that are frequently mutated in CLL, and is intended to provide information to guide treatment options. The identification of mutations in TP53, BIRC3, NOTCH1 and SF3B1 enables a more refined prognostic stratification, while the detection of TP53 mutations has therapeutic value as it guides treatment with alemtuzumab and/or steroids, which may be followed by allogeneic stem cell transplantation, Multiplicom noted. MASTR kits are compatible with leading NGS platforms, the company added.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.